Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplant is a biologic, live microbial therapy being investigated by the Hospital Universitario Dr. Jose E. Gonzalez for the treatment of chronic kidney disease (CKD). [1, 2, 3, 4] Administered as oral capsules containing fecal microbiota from healthy donors, the intervention aims to restore a healthy gut microbiome. [2-1, 2-7] This is intended to modulate the dysregulated gut-kidney axis, which may in turn decrease inflammation and slow the progression of CKD in patients with the disease, particularly those with underlying diabetes and/or hypertension. [1-2, 1-3, 2-9, 2-19] A double-blind, randomized, placebo-controlled clinical trial (NCT04361097) is evaluating this therapeutic strategy in patients with CKD stages 2, 3, and 4. [1, 2-9, 2-19]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fecal microbiota transplant (Hospital Universitario Dr. Jose E. Gonzalez).